ArticleKidney international reports2025
Treatment With Avacopan in ANCA-Associated Vasculitis With Kidney Involvement.
Article in Kidney international reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Rituximab With or Without Avacopan in ANCA-Associated Vasculitis With Severe Renal Involvement.Kidney international reports · 2026Article
- Real-world efficacy and safety of avacopan in ANCA-associated vasculitis: a retrospective comparative study.RMD open · 2026Article
- Article
- Systematic Review of Efficacy and Safety of Avacopan in Real-World Clinical Practice.Kidney international reports · 2026Article
- Complement diagnostics and therapeutics for the pediatric population: early successes and opportunities for further advancement.Frontiers in pharmacology · 2026Review
- Challenging manifestations of ANCA-associated vasculitis treated with avacopan: two case reports.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Kidney disease impacts long-term outcomes of patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). This Methods: The analysis included a study population of 268 patients (of 330 patients, 81.2%). Key efficacy outcomes were remission at week 26, sustained remission at week 52, and relapse after remission through week 52. Changes in estimated glomerular filtration rate (eGFR) were analyzed overall and stratified by baseline eGFR categories (≥ 90, 60-89, 45-59, 30-44, and 15-29 ml/min per 1.73 m Results: Remission at week 26 and sustained remission at week 52, respectively, were respectively achieved by 99 of 134 (73.9%) and 91 of 134 (67.9%) patients in the avacopan group and 95 of 134 (70.9%) and 76 of 134 (56.7%) in the prednisone taper group. Relapse rate after remission was lower in the avacopan than in the prednisone taper group (9.4% vs. 20.9%; hazard ratio [95% confidence interval, CI]: 0.43 [0.22-0.85]). Recovery of kidney function, speed of reduction in albuminuria and hematuria, and changes in GTI favored the avacopan group. No new safety issues were reported for this subset of patients. Conclusion: In patients with GPA or MPA with kidney involvement, treatment with an avacopan regimen compared with a prednisone taper regimen achieved similar rates of remission, improved recovery of kidney function, led to faster reduction in albuminuria and hematuria, and lowered GC-related toxicity, with an acceptable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.